Reporting harms more transparently in trials of cancer drugs
Author:
Publisher
BMJ
Subject
General Engineering
Reference12 articles.
1. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
3. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
4. US Food and Drug Administration. What is a serious adverse event? http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087htm
5. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review;JAMA Network Open;2024-06-03
2. Use of subjective minimizing language at hematology and oncology conferences: A systematic review;Journal of Cancer Policy;2024-03
3. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma;JAMA Network Open;2023-11-10
4. A Review of Patient-Reported Outcome Considerations in Oncologic Drugs Advisory Committee Meetings (2016-2021);JCO Oncology Practice;2023-05
5. Highlights from ecancer Choosing Wisely Nepal 2022: critical appraisal skills for evidence-based practice, 24th–25th September 2022, Kathmandu, Nepal;ecancermedicalscience;2022-11-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3